Sec Form 13G Filing - Venrock Associates VII L.P. filing for Unity Biotechnology Inc. (UBX) - 2022-02-14

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

Unity Biotechnology, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

91381U 10 1

(CUSIP Number)

 

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)
¨ Rule 13d-1(c)
x Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 91381U 10 1

 

 

1.

Name of Reporting Persons
Venrock Associates VII, L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

x(1)

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:

5.

Sole Voting Power
0

 

6.

Shared Voting Power
2,680,039(2)

 

7.

Sole Dispositive Power
0

 

8.

Shared Dispositive Power
2,680,039(2)

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
2,680,039(2)

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
4.6%(3)

 

 

12.

Type of Reporting Person (See Instructions)
PN

 

 

 

(1)Venrock Associates VII, L.P., Venrock Partners VII, L.P. and Venrock Management VII, LLC are members of a group for the purposes of this Schedule 13G/A.

(2)Consists of 2,474,163 shares owned by Venrock Associates VII, L.P. and 205,876 shares owned by Venrock Partners VII, L.P.

(3)This percentage is calculated based upon 57,724,179 shares of the Issuer’s common stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

 

2

 

CUSIP No. 91381U 10 1

 

 

1.

Name of Reporting Persons
Venrock Partners VII, L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

x(1)

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:

5.

Sole Voting Power
0

 

6.

Shared Voting Power
2,680,039(2)

 

7.

Sole Dispositive Power
0

 

8.

Shared Dispositive Power
2,680,039(2)

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
2,680,039(2)

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
4.6%(3)

 

 

12.

Type of Reporting Person (See Instructions)
PN

 

 

 

(1)Venrock Associates VII, L.P., Venrock Partners VII, L.P. and Venrock Management VII, LLC are members of a group for the purposes of this Schedule 13G/A.

(2)Consists of 2,474,163 shares owned by Venrock Associates VII, L.P. and 205,876 shares owned by Venrock Partners VII, L.P.

(3)This percentage is calculated based upon 57,724,179 shares of the Issuer’s common stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

 

3

 

CUSIP No. 91381U 10 1

 

 

1.

Name of Reporting Persons
Venrock Management VII, LLC

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

x(1)

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:

5.

Sole Voting Power
0

 

6.

Shared Voting Power
2,680,039(2)

 

7.

Sole Dispositive Power
0

 

8.

Shared Dispositive Power
2,680,039(2)

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
2,680,039(2)

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
4.6%(3)

 

 

12.

Type of Reporting Person (See Instructions)
OO

 

 

 

(1)Venrock Associates VII, L.P., Venrock Partners VII, L.P. and Venrock Management VII, LLC are members of a group for the purposes of this Schedule 13G/A.

(2)Consists of 2,474,163 shares owned by Venrock Associates VII, L.P. and 205,876 shares owned by Venrock Partners VII, L.P.

(3)This percentage is calculated based upon 57,724,179 shares of the Issuer’s common stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

 

4

 

CUSIP No. 91381U 10 1

 

Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Associates VII, L.P., a limited partnership organized under the laws of the State of Delaware (“VA7”), Venrock Partners VII, L.P., a limited partnership organized under the laws of the State of Delaware (“VP7”) and Venrock Management VII, LLC, a limited liability company organized under the laws of the State of Delaware (“VM7” and together with VA7 and VP7, the “Venrock Entities”) in respect of the common stock of Unity Biotechnology, Inc.

 

Item 1.
  (a) Name of Issuer
Unity Biotechnology, Inc.
  (b)

Address of Issuer’s Principal Executive Offices
285 East Grand Avenue

South San Francisco, CA 94080

 
Item 2.
  (a)

Name of Person Filing
Venrock Associates VII, L.P.

Venrock Partners VII, L.P.

Venrock Management VII, LLC

  (b) Address of Principal Business Office or, if none, Residence
   

New York Office:

7 Bryant Park

23rd Floor

New York, NY 10018

Palo Alto Office:

3340 Hillview Avenue

Palo Alto, CA 94304

  
  (c) Citizenship
All of the Venrock Entities were organized in Delaware.
  (d) Title of Class of Securities
Common Stock, par value $0.0001 per share.
  (e) CUSIP Number
91381U 10 1
 
Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable

 

5

CUSIP No. 91381U 10 1

Item 4. Ownership
   
  (a) Amount Beneficially Owned as of December 31, 2021:
      Venrock Associates VII, L.P. 2,680,039 (1)  
      Venrock Partners VII, L.P. 2,680,039 (1)  
      Venrock Management VII, LLC 2,680,039 (1)  
     
  (b) Percent of Class as of December 31, 2021:
      Venrock Associates VII, L.P. 4.6 %  
      Venrock Partners VII, L.P. 4.6 %  
      Venrock Management VII, LLC 4.6 %  
     
  (c) Number of shares as to which the person has, as of December 31, 2021:
       
    (i) Sole power to vote or to direct the vote
        Venrock Associates VII, L.P. 0    
        Venrock Partners VII, L.P. 0    
        Venrock Management VII, LLC 0    
       
    (ii) Shared power to vote or to direct the vote
        Venrock Associates VII, L.P. 2,680,039 (1)  
        Venrock Partners VII, L.P. 2,680,039 (1)  
        Venrock Management VII, LLC 2,680,039 (1)  
       
    (iii) Sole power to dispose or to direct the disposition of
        Venrock Associates VII, L.P. 0    
        Venrock Partners VII, L.P. 0    
        Venrock Management VII, LLC 0    
       
    (iv) Shared power to dispose or to direct the disposition of
        Venrock Associates VII, L.P. 2,680,039 (1)  
        Venrock Partners VII, L.P. 2,680,039 (1)  
        Venrock Management VII, LLC 2,680,039 (1)  

 

 
(1)These shares are owned directly as follows: 2,474,163 shares are owned by Venrock Associates VII, L.P. and 205,876 shares are owned by Venrock Partners VII, L.P. Venrock Management VII, LLC is the sole general partner of both Venrock Associates VII, L.P. and Venrock Partners VII, L.P.

 

Item 5. Ownership of Five Percent or Less of a Class
   
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
 
Item 6. Ownership of More than Five Percent on Behalf of Another Person
   
Not Applicable
 
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
   
Not Applicable
 
Item 8. Identification and Classification of Members of the Group
   
Not Applicable
 
Item 9. Notice of Dissolution of a Group
   
Not Applicable

 

Item 10. Certification
   
Not applicable.

6

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2022

 

Venrock Associates VII, L.P.   Venrock Partners VII, L.P.
       
By: Venrock Management VII, LLC   By: Venrock Management VII, LLC
Its: General Partner   Its: General Partner
         
By: /s/ David L. Stepp   By: /s/ David L. Stepp
  Name: David L. Stepp     Name: David L. Stepp
  Its: Authorized Signatory     Its: Authorized Signatory
       
       
Venrock Management VII, LLC    
       
By: /s/ David L. Stepp    
  Name: David L. Stepp    
  Its: Authorized Signatory    

 

7

 

CUSIP No. 91381U 10 1

 

EXHIBITS

 

A: Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed February 14, 2019)

 

8